UPDATE 3-Nestle invests $200 mln more in Aimmune after peanut allergy drug approval
Aimmune Therapeutics Inc said on
Wednesday the health science arm of Nestle SA will
invest an additional $200 million, days after the drugmaker won
U.S. approval for its peanut allergy therapy, touted as a
potential blockbuster.
Wednesday the health science arm of Nestle SA will
invest an additional $200 million, days after the drugmaker won
U.S. approval for its peanut allergy therapy, touted as a
potential blockbuster.
Posted by Reuters
